(Reuters) – The U.S. drug regulator has declined to approve a cancer drug tested mainly in China, the third rejection of a China-developed drug in a little over a month.
The U.S. Food and Drug Administration issued a complete response letter to the therapy for treating nasopharyngeal carcinoma, a type of head-and-neck cancer, that was developed by U.S.-based Coherus BioSciences Inc and Chinese partner Shanghai Junshi Biosciences Co Ltd, the companies said on Monday.
(Reporting by Manas Mishra and Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
